Tumor protein p63 is a member of the p53 family of transcription factors. p63 -/- mice have several developmental defects which include the lack of limbs and other tissues, such as teeth and mammary glands, which develop as a result of interactions between mesenchyme and epithelium. TP63 encodes for two main isoforms by alternative promoters (TAp63 and ΔNp63). ΔNp63 is involved in multiple ...

The ΔN-P63α isoform is the variant predominantly expressed in basal epithelial cells of skin, breast, prostate and urinary tract, its inactivation being associated with the developmental defects.

Monoclonal Antibody for studying p63. Validated for ChIP, ChIP, F, IF, IP, WB. Available in 2 sizes. Highly specific and rigorously validated in-house, p63-α (D2K8X) XP® Rabbit Monoclonal Antibody (CST #13109) is ready to ship.

AEC mutations have been found within the SAM domain of p63α isoforms [61]. Frameshift mutations on these isoforms that yield truncated C-termini lacking the PID and/or part of the SAM domain are associated with Limb-Mammary Syndrome (LMS).

Oct 17, 2023 · The full-length p63α proteins possess a C-terminus sterile alpha motif (SAM) domain, a protein-protein interaction domain, flanked by a second transactivation domain (TA2) and a transcription ...

Apr 11, 2025 · Polyclonal Antibody for studying p63. Validated for IF, WB. Highly specific and rigorously validated in-house, p63-α Antibody (CST #4892) is ready to ship.

May 1, 2008 · In addition, we showed that consistent with their transcriptional activity, p63β possessed the greatest ability to induce apoptosis (25.3±4.6% and 24.9±6.2), followed by p63γ (18.3±1.3% and 20.4±0.7), and then by p63α (7.0±0.5% and 10.6±1.4%).

Jul 12, 2016 · In the present study, we identified that MM1, a c-Myc inhibitor, specifically binds to C-termini of p63α (including ΔNp63α and TAp63α). Further study demonstrates that p63α facilitates MM1 protein degradation via proteasomal pathway, resulting in elevation of c-Myc transactivation activity.

Sep 17, 2019 · Finally, we show by mass spectrometry that TA*p63α is expressed in the breast cancer cell line Sum159 at the protein level together with mutant p53. Upon doxorubicin treatment, TA*p63α gets activated, providing a potential new tool to fight cancer.

As for the ΔN isoforms, p63α and, more profoundly, p63β inhibited growth, whereas p63γ and AEC mutants were essentially negative in this assay: in fact, ΔN518, ΔN534, and ΔN540 generated a consistently higher number of colonies.